Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in the Levant region.

Signs and Symptoms of Pompe disease

Pompe disease should be considered as part of the differential diagnosis for all children and adults presenting with limb-girdle muscle weakness and respiratory insufficiency1

Watch the below video to find out more about when to suspect Pompe disease

Late Onset Pompe Disease (LOPD)

The most common clinical manifestations are progressive proximal muscle weakness and respiratory insufficiency2

  • Respiratory muscle weakness

    • In a study of 92 children and adults with untreated LOPD, 74% of all patients had pulmonary dysfunction3
  • Proximal muscle weakness

    • In a study of 94 adults with LOPD, shoulder, abdominal, paraspinal, and hip muscles were weakened in >80% of patients4

Progressive proximal muscle weakness and respiratory insufficiency2 ultimately lead to a loss of ambulation and the need for ventilation support. Children and adults with Pompe disease show much greater heterogeneity than infants with the condition.2,5,4

In practice, some of the visible signs and symptoms you may see in people with Pompe, include a waddling gait and difficulty rising from a standing position. Watch the following videos to see how these symptoms may present:

Gower's maneuver (reliance on the upper body to rise from a seated position)

Myopathic gait (imbalances walking due to weakness in the limb-girdle)

As the disease progress' difficulty climbing stairs will become more pronounced

As will difficulty reaching overhead

Some of the symptoms people with late-onset Pompe disease may experience include2

Cardiac involvement is rare in children and in adults with Late-Onset Pompe disease but pronounced in infantile onset.

Infantile Onset Pompe Disease (IOPD) – infants typically present with pronounced hypotonia, severe cardiomegaly8 and cardiomyopathy6

  • Other signs include frequent respiratory infections, failure to reach motor milestones and difficulty feeding
  • Patients with Pompe disease will exhibit progressive muscular weakness
  • Pompe disease most commonly affects the proximal limbs and respiratory muscles, no matter the age of the patient6

Respiratory

Respiratory manifestations caused by diaphragm weakness can be the first indication of Pompe disease9-11

If left untreated, Pompe disease can lead to respiratory failure – the most common cause of death in Pompe disease2,10-12

Patients may notice the first signs of respiratory muscle dysfunction when lying down, including:10,12,13

  • Orthopnoea
  • Hypoventilation, especially when lying down
  • Sleep disordered breathing (SDB)
  • Morning headache
  • Dyspnoea at rest and after exercise
  • Chronic respiratory insufficiency

Look out for other symptoms which may point towards Pompe disease:

  • Reduced postural drop in forced vital capacity (FVC) of 25% from the sitting to the supine position4,14,15
  • Susceptibility to chest infections11
  • Post-operative failure to wean on to solid food due to muscle weakness16

References

  1. American Association of Neuromuscular & Electrodiagnostic Medicine. Muscle Nerve 2009; 40(1):149–160
  2. Winkel LP, et al. J Neurol. 2005;252 (8):875–884
  3. van der Beek NA, et al. Mol Genet Metab. 2011;104(1-2):129–136
  4. van der Beek NA, et al. Orphanet J Rare Dis. 2012 ;7:88
  5. American Association of Neuromuscular & Electrodiagnostic Medicine. Muscle Nerve 2009; 40(1):149–160
  6. Hirschhorn R, et al. The Metabolic and Molecular Basis of Inherited Disease 2001;8(3):3389–3420
  7. Kishnani PS, et al. Genet Med. 2006; 8(5):267–288
  8. Kishnani PS, et al. J Pediatr. 2006; 148:671–676
  9. Muller-Felber W, et al. Neuromuscul Disord. 2007;17(9-10):698–706
  10. Fuller D, et al. Respir Physiol Neurobiol. 2013;189(2):241–249
  11. Mellies U, et al. Respir Med. 2009;103(4):477–484
  12. Sixel B de S, et al. Jornal Brasileiro de Pneumologia 2017;43(1):54–59
  13. O’Callaghan C, et al. Respirology Case Reports 2016;4(5):e00178
  14. Manganelli F, et al. Acta Myol. 2013;32(2):82–84
  15. Gaeta M, et al. Mol Genet Metab. 2013;110(3):290–296
  16. Ruiz A, et al. PM&R. 2014;6(8 Suppl. 2):S 100
MAT-IQ-2300015-v1-Jan2023